FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150489478> ?p ?o ?g. }

• W2150489478 endingPage "280" @default.
• W2150489478 startingPage "273" @default.
• W2150489478 abstract "<h3>Objective</h3> Hospice/palliative care patients may differ from better studied populations, and data from other populations cannot necessarily be extrapolated into hospice/palliative care clinical practice. Pharmacovigilance studies provide opportunities to understand the harms and benefits of medications in routine practice. Gabapentin, a γ-amino butyric acid analogue antiepileptic drug, is commonly prescribed for neuropathic pain in hospice/palliative care. Most of the evidence however relates to non-malignant, chronic pain syndromes (diabetic neuropathy, postherpetic neuralgia, central pain syndromes, fibromyalgia). The aim of this study was to quantify the immediate and short-term clinical benefits and harms of gabapentin in routine hospice/palliative care practice. <h3>Design</h3> Multisite, prospective, consecutive cohort. <h3>Population</h3> 127 patients, 114 of whom had cancer, who started gabapentin for neuropathic pain as part of routine clinical care. <h3>Settings</h3> 42 centres from seven countries. Data were collected at three time points—at baseline, at day 7 (and at any time; immediate and short-term harms) and at day 21 (clinical benefits). <h3>Results</h3> At day 21, the average dose of gabapentin for those still using it (n=68) was 653 mg/24 h (range 0–1800 mg) and 54 (42%) reported benefits, of whom 7 (6%) experienced complete pain resolution. Harms were reported in 39/127 (30%) patients at day 7, the most frequent of which were cognitive disturbance, somnolence, nausea and dizziness. Ten patients had their medication ceased due to harms. The presence of significant comorbidities, higher dose and increasing age increased the likelihood of harm. <h3>Conclusions</h3> Overall, 42% of people experienced benefit at a level that resulted in continued use at 21 days." @default.
• W2150489478 created "2016-06-24" @default.
• W2150489478 creator A5005005390 @default.
• W2150489478 creator A5007993808 @default.
• W2150489478 creator A5026617187 @default.
• W2150489478 creator A5039366110 @default.
• W2150489478 creator A5053565464 @default.
• W2150489478 creator A5054414906 @default.
• W2150489478 creator A5055673082 @default.
• W2150489478 creator A5062780709 @default.
• W2150489478 creator A5064514171 @default.
• W2150489478 creator A5065724269 @default.
• W2150489478 creator A5068043187 @default.
• W2150489478 creator A5091483240 @default.
• W2150489478 date "2014-10-16" @default.
• W2150489478 modified "2023-10-16" @default.
• W2150489478 title "Pharmacovigilance in hospice/palliative care: net effect of gabapentin for neuropathic pain" @default.
• W2150489478 cites W16318845 @default.
• W2150489478 cites W1981435820 @default.
• W2150489478 cites W1989521638 @default.
• W2150489478 cites W1991399841 @default.
• W2150489478 cites W1994729760 @default.
• W2150489478 cites W2000445173 @default.
• W2150489478 cites W2010845171 @default.
• W2150489478 cites W2014670473 @default.
• W2150489478 cites W2067978628 @default.
• W2150489478 cites W2084567915 @default.
• W2150489478 cites W2120179103 @default.
• W2150489478 cites W2122605836 @default.
• W2150489478 cites W2160759345 @default.
• W2150489478 cites W2169423683 @default.
• W2150489478 cites W2332561007 @default.
• W2150489478 doi "https://doi.org/10.1136/bmjspcare-2014-000699" @default.
• W2150489478 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4552911" @default.
• W2150489478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26908535" @default.
• W2150489478 hasPublicationYear "2014" @default.
• W2150489478 type Work @default.
• W2150489478 sameAs 2150489478 @default.
• W2150489478 citedByCount "12" @default.
• W2150489478 countsByYear W21504894782015 @default.
• W2150489478 countsByYear W21504894782016 @default.
• W2150489478 countsByYear W21504894782017 @default.
• W2150489478 countsByYear W21504894782018 @default.
• W2150489478 countsByYear W21504894782020 @default.
• W2150489478 countsByYear W21504894782022 @default.
• W2150489478 countsByYear W21504894782023 @default.
• W2150489478 crossrefType "journal-article" @default.
• W2150489478 hasAuthorship W2150489478A5005005390 @default.
• W2150489478 hasAuthorship W2150489478A5007993808 @default.
• W2150489478 hasAuthorship W2150489478A5026617187 @default.
• W2150489478 hasAuthorship W2150489478A5039366110 @default.
• W2150489478 hasAuthorship W2150489478A5053565464 @default.
• W2150489478 hasAuthorship W2150489478A5054414906 @default.
• W2150489478 hasAuthorship W2150489478A5055673082 @default.
• W2150489478 hasAuthorship W2150489478A5062780709 @default.
• W2150489478 hasAuthorship W2150489478A5064514171 @default.
• W2150489478 hasAuthorship W2150489478A5065724269 @default.
• W2150489478 hasAuthorship W2150489478A5068043187 @default.
• W2150489478 hasAuthorship W2150489478A5091483240 @default.
• W2150489478 hasBestOaLocation W21504894781 @default.
• W2150489478 hasConcept C126322002 @default.
• W2150489478 hasConcept C142724271 @default.
• W2150489478 hasConcept C159110408 @default.
• W2150489478 hasConcept C177713679 @default.
• W2150489478 hasConcept C197934379 @default.
• W2150489478 hasConcept C204787440 @default.
• W2150489478 hasConcept C2776468701 @default.
• W2150489478 hasConcept C2776608144 @default.
• W2150489478 hasConcept C2777107010 @default.
• W2150489478 hasConcept C2778866549 @default.
• W2150489478 hasConcept C2994186709 @default.
• W2150489478 hasConcept C42219234 @default.
• W2150489478 hasConcept C57658597 @default.
• W2150489478 hasConcept C71924100 @default.
• W2150489478 hasConceptScore W2150489478C126322002 @default.
• W2150489478 hasConceptScore W2150489478C142724271 @default.
• W2150489478 hasConceptScore W2150489478C159110408 @default.
• W2150489478 hasConceptScore W2150489478C177713679 @default.
• W2150489478 hasConceptScore W2150489478C197934379 @default.
• W2150489478 hasConceptScore W2150489478C204787440 @default.
• W2150489478 hasConceptScore W2150489478C2776468701 @default.
• W2150489478 hasConceptScore W2150489478C2776608144 @default.
• W2150489478 hasConceptScore W2150489478C2777107010 @default.
• W2150489478 hasConceptScore W2150489478C2778866549 @default.
• W2150489478 hasConceptScore W2150489478C2994186709 @default.
• W2150489478 hasConceptScore W2150489478C42219234 @default.
• W2150489478 hasConceptScore W2150489478C57658597 @default.
• W2150489478 hasConceptScore W2150489478C71924100 @default.
• W2150489478 hasIssue "3" @default.
• W2150489478 hasLocation W21504894781 @default.
• W2150489478 hasLocation W21504894782 @default.
• W2150489478 hasLocation W21504894783 @default.
• W2150489478 hasLocation W21504894784 @default.
• W2150489478 hasLocation W21504894785 @default.
• W2150489478 hasLocation W21504894786 @default.
• W2150489478 hasLocation W21504894787 @default.
• W2150489478 hasOpenAccess W2150489478 @default.
• W2150489478 hasPrimaryLocation W21504894781 @default.

• next